Last updated: April 2026
IGF-1 DES (des(1-3)IGF-1) is a naturally occurring truncated form of insulin-like growth factor 1 — the first three amino acids are missing, and that changes everything. Without those amino acids, it doesn't bind IGF binding proteins, making it 10x more potent at the receptor. Inject it intramuscularly post-workout, and the localized anabolic effect is significantly greater than standard IGF-1 LR3.
The three missing amino acids make IGF-1 DES a completely different compound from a pharmacological standpoint — despite nearly identical structure.
Standard IGF-1 in circulation is 99% bound to IGF-binding proteins (IGFBPs), which slow its action and extend half-life. These IGFBPs dramatically reduce the free, bioactive fraction. IGF-1 DES lacks the N-terminal tripeptide (Gly-Pro-Glu) that IGFBPs require for binding. Result: essentially all IGF-1 DES is unbound and immediately bioactive — explaining the 10x potency difference at the receptor level.
Because IGF-1 DES is rapidly cleared (not protected by IGFBPs), it acts locally where injected. Inject into the bicep post-workout — the signal goes to that muscle. Inject into the quad — the quad gets the signal. This localized nature is why it's used for site-specific hypertrophy in research. The effect doesn't travel systemically to the degree IGF-1 LR3 does.
IGF-1 receptor activation (which IGF-1 DES strongly stimulates) triggers satellite cell proliferation and differentiation. Satellite cells are muscle stem cells required for hypertrophy beyond a certain threshold — they fuse with existing fibers, adding nuclei and enabling true fiber growth. IGF-1 DES's potent receptor activation may be particularly effective for triggering satellite cell activity in the injected muscle.
Like all IGF-1 variants, IGF-1 DES activates insulin receptor in addition to the IGF-1 receptor, lowering blood glucose. This hypoglycemic effect is real and can be severe. Always have fast-acting carbohydrates (glucose tablets, juice) immediately available. Never inject IGF-1 DES fasting or without a post-workout carbohydrate source. Never be alone the first time you use it.
The three main IGF-1 variants used in research — completely different pharmacological profiles despite similar mechanisms.
| Property | IGF-1 DES | IGF-1 LR3 | Standard IGF-1 |
|---|---|---|---|
| IGFBP Binding | None (key feature) | Very low (LR3 mod) | 99% bound normally |
| Receptor Potency | 10x vs standard IGF-1 | 2-3x vs standard | Baseline |
| Half-life | Minutes–hours | 20–30 hours | ~15 minutes |
| Effect profile | Localized (site-specific) | Systemic | Systemic (rapid) |
| Injection route | IM (intramuscular) | SubQ or IM | SubQ or IM |
| Timing | Post-workout (15-30min) | Any time (long half-life) | Post-workout |
| Hypoglycemia risk | Moderate–High | Moderate | High |
| Cancer risk concern | High (potent IGF-1R) | Moderate-High | Moderate |
IGF-1 DES carries real risks that require active management. The hypoglycemia risk is the most immediate; the cancer promotion risk is the most concerning long-term.
Supplements with solid human evidence for muscle growth — lower-risk alternatives and stack additions with better safety profiles.
For verified research-grade IGF-1 DES with third-party COAs: Swiss Chems.
IGF-1 DES is not FDA approved. This is one of the higher-risk research peptides due to hypoglycemia potential and cancer promotion concerns via IGF-1R signaling. Never use alone, always have glucose available, and avoid entirely if you have any cancer history or family history of cancer. This content is educational only — not medical advice. Consult a physician before considering any IGF-1 variant.